Page 2 - Sanofi

Sanofi's mRNA Covid-19 vaccine candidate not ready this year, CEO says

In December last year, Sanofi had said it was targeting "earliest potential approval" of the shot in the second half of 2021, following positive preclinical data

Sanofi posts stronger-than-expected result in Q4, eyes more cost cuts

The French company, which stunned investors last year with the delay of a COVID-19 vaccine candidate, confirmed an operating income margin target of 30%

France's Sanofi to help rival Pfizer-BioNTech make coronavirus vaccines

The announcement came as delays or production problems for the Pfizer-BioNTech vaccine and a vaccine from Britain''s AstraZeneca have caused political uproar across the European Union

Drugmakers to hike prices for 2021 as Covid pressure puts revenues at risk

Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise US prices on more than 300 drugs in the United States on Jan 1

Sanofi-GSK delay Covid-19 vaccine to late 2021 in setback to global fight

The two companies said they planned to start another study next February, hoping to come up with a more effective vaccine

Sputnik V developers offer to share tech with Sanofi-GSK amid vaccine delay

In late November, the Sputnik V developers also offered foreign vaccine producers their help

Sanofi offers to buy Dutch biotechnology firm Kiadis for $358.4 million

Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells

Sanofi India: Long-term investors advised to consider the stock on dips

Analysts see 19 per cent annual growth in earnings during FY20-22 with significant rise in return ratios post sale of a facility

Sanofi, GSK to supply Covax with 200 million doses of coronavirus vaccine

Sanofi and GSK have signed a Statement of Intent with Gavi, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual Covid-19 vaccines.

Sanofi, GSK to provide 200 mn doses of Covid-19 vaccine to global alliance

The facility is part of COVAX, a coalition of governments, health organisations, businesses and charities working to accelerate the development of Covid-19 vaccines

World Coronavirus Dispatch: Students across globe returning to classrooms

Boris Johnson earmarks £500 mn for mass rapid testing, Sanofi starts trials of vaccine, Steroids could reduce deaths by a third, and other pandemic-related news across the globe

Sanofi and GSK launch trial for protein-based coronavirus vaccine

PARIS (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments

Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%

As US launch of Insulin addresses a large market, improved visibility for more launches will keep sentiment elevated

Sanofi more confident about its coronavirus vaccines, trials next month

The company is working on two of the more than 150 potential vaccines being developed across the world to tackle the Covid-19 pandemic

France's Sanofi SA to buy US-based Principia Biopharma for $3.7 billion

The deal will strengthen Sanofi's research capabilities in areas such as autoimmune and allergic diseases, the companies said

Sanofi snags US biotech asset with $3.7 bn deal for Principia Biopharma

PARIS (Reuters) - Sanofi SA is to buy U.S.-based Principia Biopharma Inc for around $3.7 billion, the companies announced on Monday, marking the French healthcare company's latest acquisition in the biotech sector.

French group Sanofi to buy US firm Principia Biopharma for $3.7 billion

PARIS (Reuters) - French healthcare company Sanofi SA has agreed to buy U.S. company Principia Biopharma Inc for around $3.7 billion, the companies said on Monday, strengthening Sanofi's presence in research and development (R&D) areas.

US inks $1.5 bn deal with Moderna for 100 mn doses of Covid-19 'vaccine'

The US government previously gave Moderna around $1 billion to fund its research efforts, bringing total US funding to around $2.5 billion

Sanofi under investigation on charges including manslaughter over Depakine

Sanofi Aventis France added it had respected all its obligations regarding information provided on Depakine

European Union in talks to secure Sanofi deal for coronavirus vaccine

Armed with an emergency fund of more than 2 billion euros (1.80 billion pounds), the European Commission wants to strike deals with up to six drug makers for their vaccines